To determine the common gene expression changes governed by the SOC therapies used in ER+ breast cancer, i.e., tamoxifen, fulvestrant and palbociclib, which will further uncover signatures of sensitivity and resistance, we analyzed the Connectivity Map database13. This evidence concerns the gene UBXN11 and breast cancer.